The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
Bone-modifying agents (BMAs), including bisphosphonate (BP) and denosumab, can reduce bone-related events caused by breast cancer bone metastasis. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update” was published in Journal of Clinical O...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Surgery Concepts & Practice
2024-09-01
|
| Series: | Waike lilun yu shijian |
| Subjects: | |
| Online Access: | https://www.qk.sjtu.edu.cn/jscp/fileup/1007-9610/PDF/1737619523177-1505710455.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590617435176960 |
|---|---|
| author | LU Yujie, ZHU Siji |
| author_facet | LU Yujie, ZHU Siji |
| author_sort | LU Yujie, ZHU Siji |
| collection | DOAJ |
| description | Bone-modifying agents (BMAs), including bisphosphonate (BP) and denosumab, can reduce bone-related events caused by breast cancer bone metastasis. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update” was published in Journal of Clinical Oncology in January 2022. The new “2022 version Guideline” suggested that the use of BP should be discussed for all postmenopausal patients with early breast cancer who are indicated for adjuvant therapy. Recommended drugs included zoledronate, clodronate, and ibandronate, and the recommended duration of BP was 2-3 years. Owing to the inconsistent results of the ABCSG-18 and D-CARE trials and the lack of data directly comparing denosumab with BP in early breast cancer, the use of denosumab in adjuvant therapy was not recommended. In conclusion, the role of BP in the adjuvant treatment of early breast cancer has been further affirmed, while the value of denosumab remains unclear. |
| format | Article |
| id | doaj-art-92074bf46b4c4f778ea29c50795b8d69 |
| institution | Kabale University |
| issn | 1007-9610 |
| language | zho |
| publishDate | 2024-09-01 |
| publisher | Editorial Office of Journal of Surgery Concepts & Practice |
| record_format | Article |
| series | Waike lilun yu shijian |
| spelling | doaj-art-92074bf46b4c4f778ea29c50795b8d692025-01-23T10:48:45ZzhoEditorial Office of Journal of Surgery Concepts & PracticeWaike lilun yu shijian1007-96102024-09-01290540540810.16139/j.1007-9610.2024.05.07The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline UpdateLU Yujie, ZHU Siji0Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, ChinaBone-modifying agents (BMAs), including bisphosphonate (BP) and denosumab, can reduce bone-related events caused by breast cancer bone metastasis. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update” was published in Journal of Clinical Oncology in January 2022. The new “2022 version Guideline” suggested that the use of BP should be discussed for all postmenopausal patients with early breast cancer who are indicated for adjuvant therapy. Recommended drugs included zoledronate, clodronate, and ibandronate, and the recommended duration of BP was 2-3 years. Owing to the inconsistent results of the ABCSG-18 and D-CARE trials and the lack of data directly comparing denosumab with BP in early breast cancer, the use of denosumab in adjuvant therapy was not recommended. In conclusion, the role of BP in the adjuvant treatment of early breast cancer has been further affirmed, while the value of denosumab remains unclear.https://www.qk.sjtu.edu.cn/jscp/fileup/1007-9610/PDF/1737619523177-1505710455.pdf|breast cancer|bone-modifying agent(bma)|bisphosphonates(bp)|adjuvant treatment |
| spellingShingle | LU Yujie, ZHU Siji The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update Waike lilun yu shijian |breast cancer|bone-modifying agent(bma)|bisphosphonates(bp)|adjuvant treatment |
| title | The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update |
| title_full | The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update |
| title_fullStr | The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update |
| title_full_unstemmed | The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update |
| title_short | The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update |
| title_sort | interpretation of use of adjuvant bisphosphonates and other bone modifying agents in breast cancer asco oh cco guideline update |
| topic | |breast cancer|bone-modifying agent(bma)|bisphosphonates(bp)|adjuvant treatment |
| url | https://www.qk.sjtu.edu.cn/jscp/fileup/1007-9610/PDF/1737619523177-1505710455.pdf |
| work_keys_str_mv | AT luyujiezhusiji theinterpretationofuseofadjuvantbisphosphonatesandotherbonemodifyingagentsinbreastcancerascoohccoguidelineupdate AT luyujiezhusiji interpretationofuseofadjuvantbisphosphonatesandotherbonemodifyingagentsinbreastcancerascoohccoguidelineupdate |